| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 4.0 | 4.1 |
| Gross profit | 1.9 | 2.1 |
| Profit before tax | -13.7 | -18.2 |
| Net income | -13.7 | -18.2 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -3.4% |
|---|---|
| Gross margin | 47.2% |
| Operating margin | -368.4% |
10-Q filed with the SEC, NASDAQ: SEER. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Seer, Inc.: key numbers
- Share price
- $1.48Close, Nov 16
- Market cap
- $82.6M
- Shares outstanding
- 55.81MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Laboratory Analytical InstrumentsSIC 3826
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Seer, Inc.
All →Seer Financial Results
Seer, Inc. reported third quarter 2026 revenue of $4.0 million, a sequential increase from $3.1 million in Q2 2026, driven by consumable purchases from established customers and new pharmaceutical platform adoptions. The company ended the quarter with $198.1 million in cash and updated its full-year 2026 revenue guidance to a range of $13.5 million to $14.5 million.
- Term
- Q3 2026
“This quarter, our customers continued to demonstrate what Proteograph makes possible, from new discoveries in population-scale research to emerging applications in AI, while established customers returned to purchase consumables and new pharmaceutical customers adopted the platform.”
Omid Farokhzad, Chair and Chief Executive Officer
“Proteograph fundamentally expands the biology researchers can see with mass spectrometry. Our focus is to translate that differentiated value into sustained revenue growth by expanding sample volume within customer accounts and building relationships that support repeat use. With a strong balance sheet and growing evidence of the platform’s value, I remain confident in Seer’s opportunity and committed to building long-term value for our shareholders.”
Omid Farokhzad, Chair and Chief Executive Officer
Seer M&A Deal with Bradley L. Radoff and Michael Torok
Seer, Inc. announced that its Special Committee has concluded its strategic review and rejected unsolicited acquisition proposals from the Radoff-JEC Group ($2.55/share) and CEO Omid Farokhzad ($2.45/share). The committee determined that the proposals undervalued the company's intrinsic value and future prospects in the proteomics market, and Seer will remain an independent public company.
- Counterparty
- Bradley L. Radoff and Michael Torok (Radoff-JEC Group)
Seer Leadership Change
David Horn resigned as President, CFO, and Treasurer of Seer, Inc. effective October 1, 2026, to pursue other interests. CEO Omid Farokhzad will assume the role of President, while Charles Endweiss, the current VP of Financial Planning & Analysis, has been appointed as Treasurer and principal financial officer.